PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 38, issue 12, 2020

The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D? pp. 1283-1288

David G. T. Whitehurst, John E. Brazier, Rosalie Viney and Brendan J. Mulhern

Sustainability of Publicly Funded Health Care Systems: What Does Behavioural Economics Offer? pp. 1289-1295

Luke Connelly and Stephen Birch

Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies pp. 1297-1308

Aris Angelis, Huseyin Naci and Allan Hackshaw

Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal pp. 1309-1318

Caroline Farmer, Ash Bullement, David Packman, Linda Long, Sophie Robinson, Elham Nikram, Anthony J. Hatswell, G. J. Melendez-Torres and Louise Crathorne

Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach pp. 1319-1331

Jessica Ochalek, Haiyin Wang, Yuanyuan Gu, James Lomas, Henry Cutler and Chunlin Jin

Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles pp. 1333-1343

Ching-Yu Wang, Phuong N. Pham, Thuy N. Thai and Joshua D. Brown

Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China pp. 1345-1358

Lei Tian, Xiaomo Xiong, Qiang Guo, Yixi Chen, Luying Wang, Peng Dong and Aixia Ma

Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups pp. 1359-1372

Shweta Mital and Hai V. Nguyen

Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US” pp. 1373-1374

Richard Manning

Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US” pp. 1375-1376

William V. Padula, Sonal Parasrampuria, Mariana P. Socal, Rena M. Conti and Gerard F. Anderson

Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974–2018 pp. 1377-1377

David D. Kim, Madison C. Silver, Natalia Kunst, Joshua T. Cohen, Daniel A. Ollendorf and Peter J. Neumann

Volume 38, issue 11, 2020

On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19? pp. 1149-1151

Kamal Desai, Eric Druyts, Kevin Yan and Chakrapani Balijepalli

Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers pp. 1153-1164

Risha Gidwani and Louise Russell

Integrative Review of Managed Entry Agreements: Chances and Limitations pp. 1165-1185

Carolina Zampirolli Dias, Brian Godman, Ludmila Peres Gargano, Pâmela Santos Azevedo, Marina Morgado Garcia, Maurílio Souza Cazarim, Laís Lessa Neiva Pantuzza, Nelio Gomes Ribeiro-Junior, André Luiz Pereira, Marcus Carvalho Borin, Isabella Figueiredo Zuppo, Roberto Iunes, Tomas Pippo, Renata Curi Hauegen, Carlos Vassalo, Tracey-Lea Laba, Steven Simoens, Sergio Márquez, Carolina Gomez, Luka Voncina, Gisbert W. Selke, Livio Garattini, Hye-Young Kwon, Jolanta Gulbinovic, Aneta Lipinska, Maciej Pomorski, Lindsay McClure, Jurij Fürst, Rosana Gambogi, Carla Hernandez Ortiz, Vânia Cristina Canuto Santos, Denizar Vianna Araújo, Vânia Eloisa Araujo, Francisco de Assis Acurcio, Juliana Alvares-Teodoro and Augusto Afonso Guerra-Junior

Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer pp. 1187-1200

Erik F. Blom, Kevin ten Haaf and Harry J. Koning

A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer pp. 1201-1218

Wei Gao, Dominic Muston, Matthew Monberg, Kimmie McLaurin, Robert Hettle, Elizabeth Szamreta, Elyse Swallow, Su Zhang, Iden Kalemaj, James Signorovitch and R. Brett McQueen

A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020) pp. 1219-1236

Michael Urbich, Gary Globe, Krystallia Pantiri, Marieke Heisen, Craig Bennison, Heidi S. Wirtz and Gian Luca Di Tanna

Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome pp. 1237-1245

Edward E. Neuberger, Josh J. Carlson and David L. Veenstra

Taking the Analysis of Trial-Based Economic Evaluations to the Next Level: The Importance of Accounting for Clustering pp. 1247-1261

Mohamed El Alili, Johanna M. Dongen, Keith S. Goldfeld, Martijn W. Heymans, Maurits W. Tulder and Judith E. Bosmans

Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data pp. 1263-1275

Koen Degeling, Hui-Li Wong, Hendrik Koffijberg, Azim Jalali, Jeremy Shapiro, Suzanne Kosmider, Rachel Wong, Belinda Lee, Matthew Burge, Jeanne Tie, Desmond Yip, Louise Nott, Adnan Khattak, Stephanie Lim, Susan Caird, Peter Gibbs and Maarten IJzerman

Correction to: Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers pp. 1277-1277

Risha Gidwani and Louise Russell

Volume 38, issue 10, 2020

Future of Data Analytics in the Era of the General Data Protection Regulation in Europe pp. 1021-1029

Katarzyna Kolasa, W. Ken Redekop, Alexander Berler, Vladimir Zah and Carl V. Asche

Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development pp. 1031-1042

Meenakshi Srinivasan, Annesha White, Ayyappa Chaturvedula, Valvanera Vozmediano, Stephan Schmidt, Leo Plouffe and La’Marcus T. Wingate

Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox–Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1043-1053

Ben Wijnen, Nigel Armstrong, Bram Ramaekers, Willem Witlox, Marie Westwood, Debra Fayter, Steve Ryder, Titas Buksnys, Gill Worthy, Kate Misso, Sabine Grimm, Jos Kleijnen and Manuela Joore

Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines pp. 1055-1070

Bogdan Grigore, Oriana Ciani, Florian Dams, Carlo Federici, Saskia Groot, Meilin Möllenkamp, Stefan Rabbe, Kosta Shatrov, Antal Zemplenyi and Rod S. Taylor

Cost of Nine Pediatric Infectious Illnesses in Low- and Middle-Income Countries: A Systematic Review of Cost-of-Illness Studies pp. 1071-1094

Gatien Broucker, So Yoon Sim, Logan Brenzel, Margaret Gross, Bryan Patenaude and Dagna O. Constenla

Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness pp. 1095-1113

Clara Marquina, Ella Zomer, Sandra Vargas-Torres, Sophia Zoungas, Richard Ofori-Asenso, Danny Liew and Zanfina Ademi

Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US pp. 1115-1121

William V. Padula, Sonal Parasrampuria, Mariana P. Socal, Rena M. Conti and Gerard F. Anderson

External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions pp. 1123-1133

Sandra Lopes, Pierre Johansen, Mark Lamotte, Phil McEwan, Anamaria-Vera Olivieri and Volker Foos

Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018 pp. 1135-1145

David D. Kim, Madison C. Silver, Natalia Kunst, Joshua T. Cohen, Daniel A. Ollendorf and Peter J. Neumann

Correction to: Calculating and Interpreting ICERs and Net Benefit pp. 1147-1147

Mike Paulden

Volume 38, issue 9, 2020

Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review pp. 901-903

Paul Catchpole and Victoria Barrett

Financing Drug Innovation in the US: Current Framework and Emerging Challenges pp. 905-911

David Cutler, Noam Kirson and Genia Long

Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence? pp. 913-926

Luiza Raquel Grazziotin, Gillian Currie, Michelle M. A. Kip, Maarten J. IJzerman, Marinka Twilt, Raymond Lee and Deborah A. Marshall

Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review pp. 927-939

T. Joseph Mattingly, Bryan L. Love and Bilal Khokhar

Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States pp. 941-951

Sang Kyu Cho, Beenish S. Manzoor, Kavita R. Sail, Hélène Parisé, Arliene Ravelo, Sheila Shapouri, Tatyana Kapustyan, Simon Sharmokh, Suchin Virabhak, Matthew S. Davids and Scott Johnson

Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM pp. 953-969

Michael Willis, Adam Fridhammar, Jens Gundgaard, Andreas Nilsson and Pierre Johansen

Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis pp. 971-980

Jesse Elliott, Bláthnaid McCoy, Tammy Clifford, Beth K. Potter, George A. Wells and Doug Coyle

Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria pp. 981-994

Thomas O’Connell, Marric Buessing, Scott Johnson, Lufei Tu, Simu K. Thomas and Ioannis Tomazos

Producing Standardized Country-Level Immunization Delivery Unit Cost Estimates pp. 995-1005

Allison Portnoy, Kelsey Vaughan, Emma Clarke-Deelder, Christian Suharlim, Stephen C. Resch, Logan Brenzel and Nicolas A. Menzies

Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis pp. 1007-1020

Ning Kam, Kanila Perera, Ella Zomer, Danny Liew and Zanfina Ademi

Volume 38, issue 8, 2020

Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit? pp. 777-779

James F. O’Mahony

Why it’s Time to Abandon the ICER pp. 781-784

Mike Paulden

Calculating and Interpreting ICERs and Net Benefit pp. 785-807

Mike Paulden

Adherence to Discounting Guidelines: Evidence from Over 2000 Published Cost-Effectiveness Analyses pp. 809-818

Michelle Q. T. Kwok, Mistura A. Kareem, Michael J. Cash, Fiona Lafferty, Katy Tobin and James F. O’Mahony

A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology pp. 819-837

Lucy Cunnama, Gabriela B. Gomez, Mariana Siapka, Ben Herzel, Jeremy Hill, Angela Kairu, Carol Levin, Dickson Okello, Willyanne DeCormier Plosky, Inés Garcia Baena, Sedona Sweeney, Anna Vassall and Edina Sinanovic

Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States pp. 839-856

Kristina Burström, Fitsum Sebsibe Teni, Ulf-G. Gerdtham, Reiner Leidl, Gert Helgesson, Ola Rolfson and Martin Henriksson

Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model pp. 857-869

Jason Gordon, Oliver Darlington, Phil McEwan, Matthew Lumley, Amer Taie, Meagen Hicks, Claudie Charbonneau, Angela Blake, Neil Hawkins, Simon Goldenberg, Jonathan Otter and Mark Wilcox

Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff pp. 871-881

Tracy A. Comans, Kim-Huong Nguyen, Julie Ratcliffe, Donna Rowen and Brendan Mulhern

Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis pp. 883-892

Nils-Henning Ness, Dirk Schriefer, Rocco Haase, Benjamin Ettle and Tjalf Ziemssen

Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?” pp. 893-894

Wui-Jin Koh and Robert W. Carlson

Response to Comment on “Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice?” pp. 895-896

Audrey Tran and Vinay Prasad

Correction to: Real-World Evidence on the Patterns of Increased Societal Economic Relapse Costs in Patients with Multiple Sclerosis pp. 897-897

Nils-Henning Ness, Dirk Schriefer, Rocco Haase, Benjamin Ettle and Tjalf Ziemssen

Correction to: A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology pp. 899-900

Lucy Cunnama, Gabriela B. Gomez, Mariana Siapka, Ben Herzel, Jeremy Hill, Angela Kairu, Carol Levin, Dickson Okello, Willyanne DeCormier Plosky, Inés Garcia Baena, Sedona Sweeney, Anna Vassall and Edina Sinanovic

Volume 38, issue 7, 2020

International Valuation Protocol for the EQ-5D-Y-3L pp. 653-663

Juan M. Ramos-Goñi, Mark Oppe, Elly Stolk, Koonal Shah, Simone Kreimeier, Oliver Rivero-Arias and Nancy Devlin

Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations pp. 665-681

Matthew Franklin, James Lomas and Gerry Richardson

Health Economic Models for Metastatic Colorectal Cancer: A Methodological Review pp. 683-713

Koen Degeling, Martin Vu, Hendrik Koffijberg, Hui-Li Wong, Miriam Koopman, Peter Gibbs and Maarten IJzerman

Economic Costs of Myasthenia Gravis: A Systematic Review pp. 715-728

Erik Landfeldt, Oksana Pogoryelova, Thomas Sejersen, Niklas Zethraeus, Ari Breiner and Hanns Lochmüller

Replacing the NCCN’s Blocks with Wheels: How Should Consideration of Societal Spending be Incorporated into Oncology Practice? pp. 729-731

Audrey A. Tran and Vinay Prasad

What Value Does the NCCN Affordability Rating Really Provide to Patients, Providers, and Society? pp. 733-735

R. Brett McQueen

The Accuracy and Usefulness of the National Comprehensive Cancer Network Evidence Blocks Affordability Rating pp. 737-745

Aaron P. Mitchell, Pranammya Dey, Jennifer A. Ohn, Sara M. Tabatabai, Michael A. Curry and Peter B. Bach

Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden pp. 747-764

Julia Widén, Magnus Ivarsson, Lovisa Schalin, Polina Vrouchou, Matthias Schwenkglenks, Olof Heimbürger, Zanfina Ademi and C. Simone Sutherland

R and Shiny for Cost-Effectiveness Analyses: Why and When? A Hypothetical Case Study pp. 765-776

Rose Hart, Darren Burns, Bram Ramaekers, Shijie Ren, Daniel Gladwell, Will Sullivan, Niall Davison, Owain Saunders, Indeg Sly, Theresa Cain and Dawn Lee

Volume 38, issue 6, 2020

Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 527-536

Peter Auguste, Jill Colquitt, Martin Connock, Emma Loveman, Rachel Court, Olga Ciccarelli, Carl Counsell and Xavier Armoiry

A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway pp. 537-555

Huajie Jin, Paul Tappenden, Stewart Robinson, Evanthia Achilla, James H. MacCabe, David Aceituno and Sarah Byford

‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases pp. 557-574

Michela Meregaglia, Amanda Whittal, Elena Nicod and Michael Drummond

A Comparison of the EQ-5D-3L and EQ-5D-5L pp. 575-591

Alexander James Thompson and Alex James Turner

Modeling Heterogeneity in Patients’ Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches pp. 593-606

Marco Boeri, Daniel Saure, Alexander Schacht, Elisabeth Riedl and Brett Hauber

A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome pp. 607-618

Kelly Fust, Michael Maschio, Michele Kohli, Simron Singh, D. Mark Pritchard, Florence Marteau, Peter Myrenfors and Marion Feuilly

Examining Approaches to Estimate the Prevalence of Catastrophic Costs Due to Tuberculosis from Small-Scale Studies in South Africa pp. 619-631

Sedona Sweeney, Anna Vassall, Lorna Guinness, Mariana Siapka, Natsayi Chimbindi, Don Mudzengi and Gabriela B. Gomez

Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving pp. 633-643

Petra Baji, Miklos Farkas, Dominik Golicki, Valentina Prevolnik Rupel, Renske Hoefman, Werner Brouwer, Job Exel, Zsombor Zrubka, László Gulácsi and Márta Péntek

Comment on ‘Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal’ pp. 645-648

Ian Jacob, Karin Butler, Karolina Badora, Vanessa Gross, Annette Beiderbeck, Steve Morris and Phil McEwan

Response to Comment on “Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal” pp. 649-651

Xavier G. L. V. Pouwels, Svenja Petersohn, Vanesa Huertas Carrera, Alastair K. Denniston, Annette Chalker, Heike Raatz, Nigel Armstrong, Willem Witlox, Gill Worthy, Caro Noake, Rob Riemsma, Jos Kleijnen and Manuela A. Joore

Volume 38, issue 5, 2020

We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can pp. 427-429

Elliot B. Tapper and Jagpreet Chhatwal

Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 431-441

Xavier G. L. V. Pouwels, Svenja Petersohn, Vanesa Huertas Carrera, Alastair K. Denniston, Annette Chalker, Heike Raatz, Nigel Armstrong, Dhwani Shah, Willem Witlox, Gill Worthy, Caro Noake, Rob Riemsma, Jos Kleijnen and Manuela A. Joore

Valuing Healthcare Goods and Services: A Systematic Review and Meta-Analysis on the WTA-WTP Disparity pp. 443-458

Adriënne H. Rotteveel, Mattijs S. Lambooij, Nicolaas P. A. Zuithoff, Job Exel, Karel G. M. Moons and G. Ardine Wit

Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs pp. 459-471

Salah Ghabri, Laurent Lam, François Bocquet and Hans-Martin Spath

Economic Evaluation of Treatments for Migraine: An Assessment of the Generalizability Following a Systematic Review pp. 473-484

Matteo Ruggeri, Carlo Drago, Francesco Rosiello, Valentina Orlando and Costanza Santori

Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements pp. 485-497

Pierre Johansen, Daniel Howard, Ryan Bishop, Søren Ilsøe Moreno and Kristine Buchholtz

Feasibility, Validity and Differences in Adolescent and Adult EQ-5D-Y Health State Valuation in Australia and Spain: An Application of Best–Worst Scaling pp. 499-513

Kim Dalziel, Max Catchpool, Borja García-Lorenzo, Inigo Gorostiza, Richard Norman and Oliver Rivero-Arias

Healthcare Costs of Treating Privately Insured Patients with Acute Myeloid Leukemia in the United States from 2004 to 2014: A Generalized Additive Modeling Approach pp. 515-526

Lih-Wen Mau, Jaime M. Preussler, Linda J. Burns, Susan Leppke, Navneet S. Majhail, Christa L. Meyer, Tatenda Mupfudze, Wael Saber, Patricia Steinert and David Vanness

Volume 38, issue 4, 2020

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 317-324

Willem J. A. Witlox, Antoinette D. I. Asselt, Robert Wolff, Nigel Armstrong, Gill Worthy, Annette Chalker, Titas Buksnys, Lisa Stirk, Jos Kleijnen, Manuela A. Joore and Sabine E. Grimm

Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going? pp. 325-340

Donna Rowen, Oliver Rivero-Arias, Nancy Devlin and Julie Ratcliffe

Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review pp. 341-356

Wilfried Guets, Hareth Al-Janabi and Lionel Perrier

Preference-Based Health-Related Quality of Life Outcomes Associated with Preterm Birth: A Systematic Review and Meta-analysis pp. 357-373

Stavros Petrou, Natnaree Krabuanrat and Kamran Khan

Estimating Age- and Sex-Specific Utility Values from the CHU9D Associated with Child and Adolescent BMI z-Score pp. 375-384

Anagha Killedar, Thomas Lung, Stavros Petrou, Armando Teixeira-Pinto and Alison Hayes

A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity pp. 385-395

Tim S. Grant, Darren Burns, Christopher Kiff and Dawn Lee

Determinants of Orphan Drug Prices in Germany pp. 397-411

Franziska Worm and Charalabos-Markos Dintsios

A French Value Set for the EQ-5D-5L pp. 413-425

Luiz Andrade, Kristina Ludwig, Juan Manuel Ramos Goni, Mark Oppe and Gérard Pouvourville

Volume 38, issue 3, 2020

Reflections on NICE’s Uptake of New Methods: Past, Present, and the 2020 Review pp. 243-245

Meindert Boysen and Ian Watson

After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator? pp. 247-257

Mark Sculpher and Stephen Palmer

Challenges of Systematic Reviews of Economic Evaluations: A Review of Recent Reviews and an Obesity Case Study pp. 259-267

Elisabet Jacobsen, Dwayne Boyers and Alison Avenell

Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review pp. 269-283

Alexander Moreno-Calderón, Thai S. Tong and Praveen Thokala

Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio pp. 285-296

Fernando Alarid-Escudero and Karen M. Kuntz

Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan pp. 297-306

Haruhisa Fukuda, Yoshihiko Yano, Daisuke Sato, Sachiko Ohde, Shinichi Noto, Ryo Watanabe and Osamu Takahashi

Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome pp. 307-313

Michael Ryan, Bonnie M. K. Donato, William Irish, Christoph Gasteyger, Gilbert L’Italien and Jeffrey Laurence

Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes pp. 315-315

Laura Panattoni, Paul M. Brown, Braden Te Ao, Mark Webster and Patrick Gladding

Volume 38, issue 2, 2020

Talkin’ About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices pp. 125-134

Brendan Shaw and Jorge Mestre-Ferrandiz

One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit pp. 135-141

Christopher McCabe, Mike Paulden, Isaac Awotwe, Andrew Sutton and Peter Hall

A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders pp. 143-158

Patrick Fahr, James Buchanan and Sarah Wordsworth

Measurement Properties of Commonly Used Generic Preference-Based Measures in East and South-East Asia: A Systematic Review pp. 159-170

Xinyu Qian, Rachel Lee-Yin Tan, Ling-Hsiang Chuang and Nan Luo

Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment pp. 171-179

David D. Kim, Gregory F. Guzauskas, Caroline S. Bennette, Anirban Basu, David L. Veenstra, Scott D. Ramsey and Josh J. Carlson

Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada pp. 181-192

Feng Tian, Sherilyn K. D. Houle, Mhd. Wasem Alsabbagh and William W. L. Wong

How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness pp. 193-204

Ben Kearns, John Stevens, Shijie Ren and Alan Brennan

Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models pp. 205-216

Sabine E. Grimm, Xavier Pouwels, Bram L. T. Ramaekers, Ben Wijnen, Saskia Knies, Janneke Grutters and Manuela A. Joore

Transferability of Economic Evaluations of Treatments for Advanced Melanoma pp. 217-231

Claire Gorry, Laura McCullagh and Michael Barry

Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis pp. 233-242

T. Joseph Mattingly, Julia F. Slejko, Eberechukwu Onukwugha, Eleanor M. Perfetto, Shyamasundaran Kottilil and C. Daniel Mullins

Volume 38, issue 1, 2020

The New and Non-Transparent Cancer Drugs Fund pp. 1-4

Eifiona M. Wood and Dyfrig A. Hughes

Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians pp. 5-24

Alisa Likhitsup and Neehar D. Parikh

Economic Burden of Anxiety Disorders: A Systematic Review and Meta-Analysis pp. 25-37

Alexander Konnopka and Hannah König

A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA pp. 39-56

Elizabeth Wehler, Natalie Boytsov, Claudia Nicolay, Oscar Herrera-Restrepo and Stacey Kowal

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study pp. 57-68

Dean A. Regier, David L. Veenstra, Anirban Basu and Josh J. Carlson

Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan pp. 69-84

Luis Hernandez, Hiroyo Kuwabara, Anshul Shah, Kaoru Yamabe, Heather Burnett, Kyle Fahrbach, Maria Koufopoulou and Ryuichi Iwakiri

Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application in Multimorbidity pp. 85-95

Susanne Schmitz, Tatjana T. Makovski, Roisin Adams, Marjan Akker, Saverio Stranges and Maurice P. Zeegers

Evaluating Partitioned Survival and Markov Decision-Analytic Modeling Approaches for Use in Cost-Effectiveness Analysis: Estimating and Comparing Survival Outcomes pp. 97-108

Caitlin Smare, Khalid Lakhdari, Justin Doan, John Posnett and Sukhvinder Johal

The Value of Shorter Initial Opioid Prescriptions: A Simulation Evaluation pp. 109-119

Margrét V. Bjarnadóttir, David R. Anderson, Kislaya Prasad, Ritu Agarwal and D. Alan Nelson

Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’ pp. 121-122

Livio Garattini and Nicholas Freemantle

Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA pp. 123-123

Elizabeth Wehler, Natalie Boytsov, Claudia Nicolay, Oscar Herrera-Restrepo and Stacey Kowal